Advertisement

Current Treatment Options in Gastroenterology

, Volume 16, Issue 3, pp 289–305 | Cite as

Inflammatory Bowel Disease in the Baby to Baby Boomer: Pediatric and Elderly Onset of IBD

  • Anita Afzali
  • Seymour Katz
Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Intractable Disease in the Elderly: When Conventional Therapy Fails

Abstract

Purpose of review

Early- and late-onset of inflammatory bowel disease (IBD) may perhaps be etiologically distinct and potentially attributed to genetics, environmental or microbial factors. We review disease factors and clinical characteristics, as well as unique management and treatment strategies to consider when caring for the “baby” or “baby boomer” with IBD.

Recent findings

Around 25% of cases of initial diagnosis of IBD is made before the age of 18 years old, and another 15–20% made after the age of 60. Crohn’s disease (CD) typically presents as ileocolonic and stricturing or penetrating phenotype among early-onset, whereas among late-onset, it is mainly colonic and inflammatory. Pediatric ulcerative colitis (UC) is mostly pan-colonic versus primarily left-sided among the elderly. Treatment goal for both age groups is primarily symptom control, with growth and development also considered among pediatric patients. Due to alterations in pharmacokinetics, careful monitoring and reduced dose should be considered. A multidisciplinary care team is necessary to ensure better clinical outcomes.

Summary

Onset of disease at either spectrum of age requires careful management and treatment, with both unique disease- and age-appropriate factors carefully considered.

Keywords

Pediatric IBD Elderly IBD Early-onset and late-onset IBD Pediatric-adult transition of IBD care 

Notes

Author contributions

Afzali A: performed the research and wrote the paper. Katz S: contributed critical revision and intellectual content.

Compliance with ethical standards

Conflict of interest

Anita Afzali reports grants from Abbvie and UCB; honoraria from Abbvie, UCB, Takeda, Janssen, and IBD Horizons, and payment and travel accommodations from UCB, Takeda, Abbvie, IBD Horizons and Janssen.

Seymour Katz has no conflict of interests to disclose.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.CrossRefPubMedGoogle Scholar
  2. 2.
    Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel disease with time, based on systematic review. Gastroenterology. 2012;142:46–54.CrossRefPubMedGoogle Scholar
  3. 3.
    Sandler RS, Eisen GM. Epidemiology of inflammatory bowel disease. In: Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: Saunders; 2000. p. 89–112.Google Scholar
  4. 4.
    Shashidar H, Integlia MJ, Grand RJ. Clinical manifestations of pediatric inflammatory bowel disease. In: Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: Saunders; 2000. p. 326–34.Google Scholar
  5. 5.
    • Benchimol EI, Mack DR, Nguyen GC, et al. Incidence, outcomes and health services burden of very early onset of inflammatory bowel disease. Gastroenterology. 2014;147:803–13. Summarizes disease characteristics and outcomes of early and very early onset of IBD.CrossRefPubMedGoogle Scholar
  6. 6.
    •• Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther. 2014;39:459–77. This review summarizes disease characteristics and management of the elderly with IBD.CrossRefPubMedGoogle Scholar
  7. 7.
    Ruel J, Ruane D, Mehandru S, et al. IBD across the age spectrum—is it the same disease? Nat Rev Gastroenterol Hepatol. 2013;11:88–98.CrossRefPubMedGoogle Scholar
  8. 8.
    Afzali A, Cross RK. Racial and ethnic minorities with inflammatory bowel disease in the United States: a systematic review of disease characteristics and differences. Inflamm Bowel Dis. 2016;22:2023–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Louis E. When it is not inflammatory bowel disease: differential diagnosis. Curr Opin Gastroenterol. 2015;31:283–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Dabritz J, Gerner P, Enninger A, et al. Inflammatory bowel disease in childhood and adolescence. Dtsch Arztebl Int. 2017;114:331–8.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Del Val JH. Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol. 2011;17:2734–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Nimmons D, Limdi JK. Elderly patients with inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7:51–65.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Harper PC, McAuliffe TL, Beeken WL. Crohn’s disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. Arch Intern Med. 1986;146:753–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Wagtmans MJ, Verspaget HW, Lamers CB, et al. Crohn’s disease in the elderly: a comparison with young adults. J Clin Gastroenterol. 1998;27:129–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519–25.CrossRefPubMedGoogle Scholar
  16. 16.
    Virta LJ, Saarinen MM, Kolho KL. Inflammatory bowel disease incidence is on the continuous rise among all paediatric patients except for the very young: a nationwide registry-based study on 28-year follow up. J Crohn's Colitis. 2017;11:150–6.CrossRefGoogle Scholar
  17. 17.
    Gasparetto M and Guariso G. Gastroenterology research and practice. Volume 2013, Article ID 829040, 12 pages.Google Scholar
  18. 18.
    Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254–61.CrossRefPubMedGoogle Scholar
  19. 19.
    Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Ananthakrishnan AN, McGinley EL, Binion DG, et al. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Manosa M, Calafat M, de Frandisco R, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicenter, case-control study. Aliment Pharmacol Ther. 2018:1–10.Google Scholar
  23. 23.
    Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence and survival. Gut. 2000;46:336–43.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn’s disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence and survival. Gastroenterology. 1998;114:1161–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Jeuring SF, Van den Heuvel TR, Zeegers MP, et al. Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age—an increasing distinct entity? Inflamm Bowel Dis. 2016;22:1425–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Gower-Rousseau C, Vasseur F, Fumery M, Savoye G, Salleron J, Dauchet L, et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis. 2013;45:89–94.CrossRefPubMedGoogle Scholar
  27. 27.
    Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol. 2007;102:2804–12.CrossRefPubMedGoogle Scholar
  28. 28.
    Hyam J, Crandall W, Kugathasan S, et al. REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132:863–73.CrossRefGoogle Scholar
  29. 29.
    Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of pediatric IBD consortium registry. J Pediatr. 2005;146:35–40.CrossRefPubMedGoogle Scholar
  30. 30.
    Paul TM, Birnbaum AM, Pal DKP, et al. Distinct phenotype of early childhood inflammatory bowel disease. J Clin Gastroenterol. 2006;40:583–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Limbergen JV, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–22.CrossRefPubMedGoogle Scholar
  32. 32.
    Moran CJ. Very early onset inflammatory bowel disease. Semin Pediatr Surg. 2017;26:356–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Meinzer U, Idestrom M, Alberti C, et al. Ileal involvement is age dependent in pediatric Crohn’s disease. Inflamm Bowel Dis. 2005;11:639–44.CrossRefPubMedGoogle Scholar
  34. 34.
    Shaoul R, Karban A, Reif S, Weiss B, Shamir R, Tamir A, et al. Disease behavior in children with Crohn’s disease: the effect of disease duration, ethnicity, genotype, and phenotype. Dig Dis Sci. 2009;54:142–50.CrossRefPubMedGoogle Scholar
  35. 35.
    Mamula P, Telega GW, Markowitz JE, Brown KA, Russo PA, Piccoli DA, et al. Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol. 2002;97:2005–10.CrossRefPubMedGoogle Scholar
  36. 36.
    Prenzel F, Uhlig HH. Frequency of indeterminate colitis in children and adults with IBD – a meta-analysis. J Crohns Colitis. 2009;3:277–81.CrossRefPubMedGoogle Scholar
  37. 37.
    Aloi M, Lionetti P, Barabino A, Guariso G, Costa S, Fontana M, et al. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:597–605.CrossRefPubMedGoogle Scholar
  38. 38.
    Cannioto Z, Berti I, Martelossi S, Bruno I, Giurici N, Crovella S, et al. IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur J Pediatr. 2009;168:149–55.CrossRefPubMedGoogle Scholar
  39. 39.
    Ruemmele FM, El Khoury MG, Talbotec C, et al. Characteristics of inflammatory bowel disease with onset during the first year of life. J Pediatr Gastroenterol Nutr. 2006;43:603–9.CrossRefPubMedGoogle Scholar
  40. 40.
    • Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris Classification. Inflamm Bowel Dis. 2011;17:1314–21. Given differences in disease characteristics and natural course history of early and very-early onset of IBD, the authors propose a modification of the Montreal classification of IBD.CrossRefPubMedGoogle Scholar
  41. 41.
    Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease. Gastroenterology. 2012;143:285–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Greth J, Torok HP, Koenig A, et al. Comparison of inflammatory bowel disease at younger and older age. Eur J Med Res. 2004;9:552–4.PubMedGoogle Scholar
  43. 43.
    Polito JM, Childs B, Mellits ED, et al. Crohn’s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111:580–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis. 2011;5:5–13.CrossRefPubMedGoogle Scholar
  45. 45.
    Juneja M, Baidoo L, Schwartz MB, Barrie A, Regueiro M, Dunn M, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.CrossRefPubMedGoogle Scholar
  46. 46.
    Riegler G, Tartaglione MT, Carratu R, et al. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). Dig Dis Sci. 2000;45:462–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009;41:1335–40.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kugathasan S, Baldassano RN, Bradfield JP, Sleiman PMA, Imielinski M, Guthery SL, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet. 2008;40:1211–5.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Levine A, Kugathasan S, Annese V, Biank V, Leshinsky-Silver E, Davidovich O, et al. Pediatric-onset Crohn’s colitis is characterized by genotype-dependent age-related susceptibility. Inflamm Bowel Dis. 2007;13:1509–15.CrossRefPubMedGoogle Scholar
  50. 50.
    Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–45.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Moran CJ, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D, et al. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 2013;19:115–23.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Connelly TM, Berg AS, Harris L III, Brinton D, Deiling S, Koltun WA. Genetic determinants associated with early age diagnosis of IBD. Dis Colon Rectum. 2015;58:321–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Kelsen JR, Grossman AB, Pauly-Hubbard H, Gupta K, Baldassano RN, Mamula P. Infliximab therapy in pediatric patients 7 years of age and younger. J Pediatr Gastroenterol Nutr. 2014;59:758–62.CrossRefPubMedGoogle Scholar
  54. 54.
    Chhaya V, Pollok RCG, Cecil E, Subramanian V, Curcin V, Majeed A, et al. Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study. Aliment Pharmacol Ther. 2015;42:990–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 2000;31:8–15.CrossRefPubMedGoogle Scholar
  56. 56.
    Ruemmele FM, Roy CC, Levy F, et al. Nutrition as primary therapy in pediatric Crohn’s disease: fact or fantasy? J Pediatri. 2000;136:285–91.CrossRefGoogle Scholar
  57. 57.
    Suskind DL, Wahbeh G, Cohen SA, Damman CJ, Klein J, Braly K, et al. Patients perceive clinical benefit with the specific carbohydrate diet for inflammatory bowel disease. Dig Dis Sci. 2016;61:3255–60.CrossRefPubMedGoogle Scholar
  58. 58.
    Obih C, Wahbeh G, Lee D, Braly K, Giefer M, Shaffer ML, et al. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. Nutrition. 2016;32:418–25.CrossRefPubMedGoogle Scholar
  59. 59.
    Engstrom I. Inflammatory bowel disease in children and adolescent: mental health and family functioning. J Pediatr Gastroenterol Nutr. 1999;28:S28–33.CrossRefPubMedGoogle Scholar
  60. 60.
    Parian A, Ha CY. Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1392–400.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Cucchiara S, Lebba V, Conte MP, et al. The microbiota in inflammatory bowel disease in different age groups. Dig Dis Sci. 2009;27:252–8.CrossRefGoogle Scholar
  62. 62.
    Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128:92–105.CrossRefPubMedGoogle Scholar
  63. 63.
    Cambier J. Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol Rev. 2005;205:50–6.CrossRefGoogle Scholar
  64. 64.
    Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Kim M, Katz S, Green J. Drug management in the elderly IBD patient. Curr Treat Options Gastroenterol. 2015;13:90–104.CrossRefPubMedGoogle Scholar
  66. 66.
    Katz S, Surawicz C, Pardi DS. Management of the elderly patients with inflammatory bowel disease: practical considerations. Inflamm Bowel Dis. 2013;19:2257–72.CrossRefPubMedGoogle Scholar
  67. 67.
    Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.CrossRefPubMedGoogle Scholar
  68. 68.
    Desai AI, Zator ZA, deSilva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:309–15.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Lobaton T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:441–51.CrossRefPubMedGoogle Scholar
  70. 70.
    Beaugeri L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefGoogle Scholar
  71. 71.
    Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients inflammatory bowel disease. Gastroenterology. 2008;134:929–36.CrossRefPubMedGoogle Scholar
  72. 72.
    Everhov AH, Halfvarson J, Myrelid P, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2017:1–11.Google Scholar
  73. 73.
    Schaefer ME, Machan JT, Kawatu D, Langton CR, Markowitz J, Crandall W, et al. Factors that determine risk for surgery in pediatric patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2010;8:789–94.CrossRefPubMedGoogle Scholar
  74. 74.
    Nordenvall C, Rosvall O, Bottai M. Surgical treatment in childhood-onset inflammatory bowel disease—a nationwide register-based study of 4695 incident patients in Sweden 2002-2014. J Crohns Colitis. 2018;12:157–66.CrossRefPubMedGoogle Scholar
  75. 75.
    Stokes AL, Kulaylat AN, Rocourt DV, et al. Rates and trends for inpatient surgeries in pediatric Crohn’s disease in the United States form 2003-2012. J Pediatr Surg 2017.Google Scholar
  76. 76.
    Nguyen G, Berstein CN, Benchimol EI. Risk of surgery and mortality in elderly-onset inflammatory bowel disease: a population-based cohort study. Inflamm Bowel Dis. 2017;23:218–23.CrossRefPubMedGoogle Scholar
  77. 77.
    Ananthakrishnan AN, Shi HY, Tang W, Law CCY, Sung JJY, Chan FKL, et al. Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 2016;10:1224–36.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, et al. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med. 2015;163:262–70.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    John ES, Katz K, Saxena M, Chokhavatia S, Katz S. Management of inflammatory bowel disease in the elderly. Curr Treat Options Gastroenterol. 2016;14:285–304.CrossRefPubMedGoogle Scholar
  80. 80.
    Bollegala N, Jackson TD, Nguyen GC. Increased postoperative mortality, and complications among elderly patients with inflammatory bowel disease: an analysis of the national surgical quality improvement program cohort. Clin Gastroenterol Hepatol. 2016;14:1274–81.CrossRefPubMedGoogle Scholar
  81. 81.
    Alexakis C, Saxena S, Chhaya V, Cecil E, Curcin V, Pollok R. Do thiopurines reduce the risk of surgery in elderly onset inflammatory bowel disease? A 20-year national population-based cohort study. Inflamm Bowel Dis. 2017;23:672–80.CrossRefPubMedGoogle Scholar
  82. 82.
    Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2014;13:847–58.CrossRefPubMedGoogle Scholar
  83. 83.
    Kochar B, Long MD, Galanko J, Raffals LE, Ananthakrishnan A, Sandler RS. Inflammatory bowel disease is similar in patients with older onset and younger onset. Inflamm Bowel Dis. 2017;23:1187–94.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    •• Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease. J Clin Gastroenterol. 2012;46:581–9. Summarizes disease characteristics and management of pediatric-onset of IBD.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Dulai PS, Thompson KD, Blunt H, et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–51.CrossRefPubMedGoogle Scholar
  86. 86.
    Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patient with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41.CrossRefPubMedGoogle Scholar
  87. 87.
    de Ridder L, Turner D, Wilson DC, Koletzko S, Martin-de-Carpi J, Fagerberg UL, et al. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the Porto Pediatric IBD Group. Inflamm Bowel Dis. 2014;20:291–300.CrossRefPubMedGoogle Scholar
  88. 88.
    Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al. CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefPubMedGoogle Scholar
  89. 89.
    Cheddani H, Dauchet L, Fumery M, et al. Cancer in elderly onset inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2016;111:1428–36.CrossRefPubMedGoogle Scholar
  90. 90.
    Wang YR, Cangemi JR, Loftus EV Jr, et al. Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:444–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determine therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–38.CrossRefPubMedGoogle Scholar
  92. 92.
    Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology. 2004;126:1550–60.CrossRefPubMedGoogle Scholar
  93. 93.
    Afzali A, Wahbeh G. Transition of pediatric to adult care in inflammatory bowel disease: is it as easy as 1, 2, 3? World J Gastroenterol. 2017;23:3624–31.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patient with multiple conditions. N Engl J Med. 2004;351:2870–4.CrossRefPubMedGoogle Scholar
  95. 95.
    Long MD, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS. Risk factors for depression in the elderly inflammatory bowel disease population. J Crohns Colitis. 2014;8:113–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.The Ohio State University Inflammatory Bowel Disease CenterColumbusUSA
  2. 2.Division of Gastroenterology, Hepatology, and NutritionThe Ohio State University Wexner Medical CenterColumbusUSA
  3. 3.NYU Langone Nassau Gastroenterology AssociatesNew York University School of MedicineGreat NeckUSA

Personalised recommendations